 Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc NASDAQ: CGEM lead program, CLN-081TAS6417. Under the agreement, Taiho will acquire Cullinan Oncologys subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan to CLN-081. 